News·Opentensor YouTube·May 8, 2026, 21:40 UTC

Bittensor Is Being Used to Make Drugs

Nova is using Bittensor to accelerate drug discovery. In this episode, Micaela, Pedro, Amanita, and udorf walk through Nova’s current work across three incentive mechanisms: small molecules, nanobodies, and open-source search algorithms for chemical space. The discussion covers how miners are helping search through billions of candidate molecules, how Nova filters subnet outputs into compounds that can be synthesized and tested, and how automated labs and agentic chemistry pipelines could compress the early stages of drug R&D. The team also explains the nanobody competition, where miners design biologically plausible antibody fragments for real biomedical targets, including oncology-related targets. Later in the episode, the conversation shifts to the conviction upgrade on testnet: why locked stake matters + how a 21-day unlock window could change subnet governance CHAPTERS 00:00:10 Introduction 00:00:49 Nova’s drug discovery mission 00:03:58 Nova’s three incentive mechanisms 00:05:00 Triple reuptake inhibitors 00:06:08 Searching 60 billion molecules 00:10:00 From subnet outputs to synthesizable compounds 00:10:45 OnePot and automated chemistry 00:18:20 Nova Blueprint 00:20:00 65x faster molecular search 00:22:30 Nanobodies explained 00:25:00 The nanobody scoring pipeline 00:30:00 Cancer, inflammation, and anti-aging targets 00:32:30 What else can be automated? 00:37:30 Conviction mode 00:39:00 What conviction is designed to solve 00:40:00 Striker’s critique 00:45:00 21-day unlocks and investor protection 00:52:30 Governance and token-holder power 00:57:30 Founder liquidity and public unlocks 01:00:00 Programmatic treasury management 01:05:00 Final positions

Read the article at Opentensor YouTube ↗

Taosis indexes announcements, articles and releases about Bittensor subnets from their own channels and keeps a record of each. The text above is the source’s; the figures are read from the chain by Taosis.